Methods of identifying HIV patients sensitive to therapy with gp120 CD4 binding site-directed antibodies

A method of treating HIV in a human subject in need thereof, the method comprising the following ordered steps:

• a) First, identifying a human subject who is infected with an HIV or a population of HIV expressing a gp120 comprising the following amino acid residues:
• I201 and F353, wherein the amino acid positions are with reference to SEQ ID NO:
• 3;
• and
• b) Second, administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that comprises a heavy-chain variable domain (VH) comprising a VH-complementarity determining region (CDR)1, a VH-CDR2, and a VH-CDR3;
• and a light-chain variable domain (VL) comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3;
• (i) wherein the VH-CDR1, the VH-CDR2, the VH-CDR3, the VL-CDR1, the VL-CDR2, and the VL-CDR3 comprise the sequences set forth, respectively, in:
• SEQ ID NOs:
• 7, 8, 9, 10, 11 and 12;
• wherein the CDRs are according to Kabat;
• (ii) wherein the VH-CDR1, the VH-CDR2, the VH-CDR3, the VL-CDR1, the VL-CDR2, and the VL-CDR3 comprise the sequences set forth, respectively, in:
• SEQ ID NOs:
• 45, 46, 47, 48, 49 and 50;
• wherein the CDRs are according to Chothia;
• (iii) wherein the VH-CDR1, the VH-CDR2, the VH-CDR3, the VL-CDR1, the VL-CDR2, and the VL-CDR3 comprise the sequences set forth, respectively, in:
• SEQ ID NOs:
• 80, 81, 82, 48, 49 and 12;
• wherein the CDRs are according to IMGT;
• or
• (iv) wherein the VH-CDR1, the VH-CDR2, the VH-CDR3, the VL-CDR1, the VL-CDR2, and the VL-CDR3 comprise the sequences set forth, respectively, in:
• SEQ ID NOs:
• 105, 106, 107, 108, 109 and 50;
• wherein the CDRs are according to Honegger.